Compare FOCL & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOCL | ORGO |
|---|---|---|
| Founded | N/A | 1985 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.7M | 239.3M |
| IPO Year | 1998 | 2016 |
| Metric | FOCL | ORGO |
|---|---|---|
| Price | $4.31 | $1.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 174.0K | ★ 880.5K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1600.00 |
| EPS | ★ N/A | N/A |
| Revenue | $70,527,000.00 | ★ $564,169,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $26.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.63 | ★ 17.04 |
| 52 Week Low | $4.09 | $1.54 |
| 52 Week High | $6.40 | $7.08 |
| Indicator | FOCL | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 28.05 | 39.59 |
| Support Level | N/A | $1.54 |
| Resistance Level | $5.64 | $2.64 |
| Average True Range (ATR) | 0.33 | 0.13 |
| MACD | -0.24 | -0.03 |
| Stochastic Oscillator | 9.09 | 40.96 |
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.